Heart2Save Announces a Product for Identification of Atrial Fibrillation at Home
Heart2Save, a Finnish startup with roots in Kuopio University Hospital, announced a Movesense powered solution that allows the user him/herself to identify atrial fibrillation at an early stage. The company’s ambitious vision is to reduce strokes caused by atrial fibrillation and thus save lives and secure healthier life years.
The AiVoni Analysis Service includes a device with which the user can identify heart arrhythmia anywhere, anytime. When the user measures ECG, the AiVoni Analysis Service analyses the ECG in order to determine whether there is a potentially dangerous atrial fibrillation or, for example, harmless extrasystoles. The measurement also generates a normal ECG strip that makes it easier to seek medical help.
Atrial fibrillation is a heart arrhythmia that causes symptoms for some people but is asymptomatic for others, which means that the person in question doesn’t even suspect having atrial fibrillation. The most feared consequence of atrial fibrillation is a cerebral stroke – atrial fibrillation increases the risk for a stroke with up to five times and causes no less than 40% of cerebral strokes.
“A stroke is a common and miserable condition. Every fifth one of us will get a stroke before old age (75 years). One-third of those who get a stroke die, one-third get reduced functional ability, and one-third recover. This is why we should put effort into stroke prevention. A stroke is not just an ‘old people’s’ condition, as every fourth person that gets a stroke is still in working-age,” says Helena Jäntti, CEO of Heart2Save.
Heart2Save’s device is in the final phase of medical device approval. It has thus gone through the same process as devices that are used in hospitals, which ensures product quality and patient safety.
“Our Movesense sensor is suited for a wide range of use, both in exercise and in health and well-being. It is really exciting to get the first medical heart rate product with Movesense on the market. During the project, we worked together with Heart2Save’s team to get the clinical validation required for the regulatory process. We are looking forward to both new ways of use for the sensor and the success of Heart2Save’s product,” says Jussi Kaasinen, Director, Emerging Business, Suunto.
In the next step, Heart2Save will develop a solution that continuously monitors the heart rhythm and alerts when atrial fibrillation is suspected, so that the user can take an ECG and seek help for ensuring a diagnosis.
The new product can be purchased from Heart2Save’s web shop in the beginning of autumn, when the medical device approval is concluded.
